Esperion Therapeutics Inc. (Nasdaq: ESPR) stock plunged $5.98 to close at $23.67 after rival Amgen Inc. (Nasdaq: AMGN) reported disappointing results for its cholesterol drug Repatha. Shares of Amgen plummeted $11.50 to close at $168.61.
Esperion falls on Amgen's disappointment
March 17, 2017 at 19:05 PM EDT
